Identification

Name
Cimetidine
Accession Number
DB00501  (APRD00568)
Type
Small Molecule
Groups
Approved
Description

A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. [PubChem]

Structure
Thumb
Synonyms
  • 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine
  • 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine
  • Cimetag
  • Cimetidin
  • Cimetidina
  • Cimétidine
  • Cimetidinum
  • N-Cyano-n'-methyl-n''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
  • N''-cyano-N-methyl-n'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
  • Tagamet hb 200
  • Ulcerfen
External IDs
NSC-335308 / SKF 92334 / SKF-92334
Product Ingredients
IngredientUNIICASInChI Key
Cimetidine HydrochlorideWF1049167370059-30-2QJHCNBWLPSXHBL-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cimetidine 200 Tab 200mgTablet200 mgOralPro Doc Limitee1984-12-312009-07-23Canada
Cimetidine Tab 300mgTablet300 mgOralPro Doc Limitee1983-12-312010-07-13Canada
Cimetidine Tab 400mgTablet400 mgOralPro Doc Limitee1984-12-312009-07-23Canada
Cimetidine Tab 600mgTablet600 mgOralPro Doc Limitee1984-12-312012-07-23Canada
Dom-cimetidineTablet600 mgOralDominion Pharmacal2000-06-19Not applicableCanada
Dom-cimetidineTablet200 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-cimetidineTablet400 mgOralDominion Pharmacal2000-06-19Not applicableCanada
Dom-cimetidineTablet800 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-cimetidineTablet300 mgOralDominion Pharmacal2000-06-19Not applicableCanada
Gen-cimetidine Tablets 200mgTablet200 mgOralGenpharm Ulc1997-05-302009-08-05Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Cimetidine Tab 200mgTablet200 mgOralApotex Corporation1982-12-31Not applicableCanada
Apo Cimetidine Tab 300mgTablet300 mgOralApotex Corporation1982-12-31Not applicableCanada
Apo Cimetidine Tab 400mgTablet400 mgOralApotex Corporation1983-12-31Not applicableCanada
Apo Cimetidine Tab 600mgTablet600 mgOralApotex Corporation1983-12-31Not applicableCanada
Apo-cimetidine Oral SolutionLiquid300 mgOralApotex Corporation2001-01-05Not applicableCanada
Apo-cimetidine Tab 800mgTablet800 mgOralApotex Corporation1988-12-31Not applicableCanada
CimetidineTablet, film coated300 mg/1Oralbryant ranch prepack2003-11-24Not applicableUs
CimetidineTablet, film coated400 mg/1OralAidarex Pharmaceuticals LLC2004-02-02Not applicableUs
CimetidineTablet, film coated400 mg/1OralDispensing Solutions, Inc.2010-05-26Not applicableUs
CimetidineTablet, film coated400 mg/1OralA S Medication Solutions2004-02-02Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid ReducerTablet200 mg/1OralKroger2015-10-21Not applicableUs
Acid ReducerTablet200 mg/1OralRite Aid2005-07-082017-11-14Us
Cimetidine Acid ReducerTablet200 mg/1OralWalgreen2001-03-27Not applicableUs
DG Health Heartburn ReliefTablet200 mg/1OralDolgencorp2010-03-022017-11-18Us
Equaline Acid ReducerTablet200 mg/1OralSupervalu2004-09-15Not applicableUs
Equate CimetidineTablet200 mg/1OralWalmart Stores2006-09-27Not applicableUs
Gaviscon All-nightTablet100 mgOralGlaxosmithkline IncNot applicableNot applicableCanada
Gaviscon PreventTablet100 mgOralGlaxosmithkline Inc1998-08-172002-07-31Canada
Gaviscon Prevent Extra StrengthTablet200 mgOralGlaxosmithkline IncNot applicableNot applicableCanada
Good Neighbor Pharmacy Heartburn ReliefTablet200 mg/1OralAmerisource Bergen2000-01-05Not applicableUs
International/Other Brands
Cimetag (Julphar) / Tagamet HB200 (GlaxoSmithKline) / Ulcedine / Ulcerfen (Finadiet) / Ulcimet (Farmasa)
Categories
UNII
80061L1WGD
CAS number
51481-61-9
Weight
Average: 252.339
Monoisotopic: 252.115715232
Chemical Formula
C10H16N6S
InChI Key
AQIXAKUUQRKLND-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
IUPAC Name
(Z)-1-cyano-2-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
SMILES
C\N=C(\NCCSCC1=C(C)NC=N1)NC#N

Pharmacology

Indication

For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.

Structured Indications
Pharmacodynamics

Cimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.

Mechanism of action

Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.

TargetActionsOrganism
AHistamine H2 receptor
antagonist
Human
Absorption

Rapid 60-70%

Volume of distribution
Not Available
Protein binding

15-20%

Metabolism

Hepatic

Route of elimination

The principal route of excretion of cimetidine is the urine.

Half life

2 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include nausea, vomiting, diarrhea, increased saliva production, difficulty breathing, and a fast heartbeat.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Cimetidine Action PathwayDrug action
Cimetidine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cimetidine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cimetidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cimetidine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Cimetidine.Experimental, Illicit
AcenocoumarolCimetidine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Cimetidine.Approved
AcetohexamideThe serum concentration of Acetohexamide can be increased when it is combined with Cimetidine.Investigational, Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Cimetidine.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Cimetidine.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Cimetidine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Cimetidine.Approved, Investigational
AlaproclateThe metabolism of Alaproclate can be decreased when combined with Cimetidine.Experimental
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Cimetidine.Approved, Illicit
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Cimetidine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Cimetidine.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Cimetidine.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Cimetidine.Approved, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Cimetidine.Experimental, Investigational
AmineptineThe metabolism of Amineptine can be decreased when combined with Cimetidine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Cimetidine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Cimetidine.Approved
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Cimetidine.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Cimetidine.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Cimetidine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Cimetidine.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Cimetidine.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Cimetidine.Approved, Vet Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Cimetidine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Cimetidine.Approved
AmrinoneThe serum concentration of Amrinone can be increased when it is combined with Cimetidine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Cimetidine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Cimetidine.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Cimetidine.Approved
AprepitantThe metabolism of Aprepitant can be decreased when combined with Cimetidine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Cimetidine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Cimetidine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Cimetidine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Cimetidine.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Cimetidine.Approved, Investigational
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Cimetidine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Cimetidine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Cimetidine.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Cimetidine.Approved
AzelnidipineThe serum concentration of Azelnidipine can be increased when it is combined with Cimetidine.Approved, Investigational
AzimilideThe serum concentration of Azimilide can be increased when it is combined with Cimetidine.Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Cimetidine.Approved
BencyclaneThe serum concentration of Bencyclane can be increased when it is combined with Cimetidine.Experimental
BenidipineThe serum concentration of Benidipine can be increased when it is combined with Cimetidine.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Cimetidine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Cimetidine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Cimetidine.Approved
Benzylpenicilloyl PolylysineCimetidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe serum concentration of Bepridil can be increased when it is combined with Cimetidine.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Cimetidine.Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Cimetidine.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cimetidine.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Cimetidine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Cimetidine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cimetidine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cimetidine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Cimetidine.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Cimetidine.Approved, Illicit
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Cimetidine.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Cimetidine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Cimetidine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Cimetidine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Cimetidine can be increased when it is combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Cimetidine.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Cimetidine.Approved
CapecitabineThe serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Cimetidine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Cimetidine.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Cimetidine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Cimetidine.Approved
CarboxyamidotriazoleThe serum concentration of Carboxyamidotriazole can be increased when it is combined with Cimetidine.Investigational
CarbutamideThe serum concentration of Carbutamide can be increased when it is combined with Cimetidine.Experimental
CariprazineThe metabolism of Cariprazine can be decreased when combined with Cimetidine.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Cimetidine.Approved
CarmustineCimetidine may increase the myelosuppressive activities of Carmustine.Approved
CaroverineThe serum concentration of Caroverine can be increased when it is combined with Cimetidine.Experimental
CarteololThe metabolism of Carteolol can be decreased when combined with Cimetidine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Cimetidine.Approved, Investigational
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Cimetidine.Approved
CefpodoximeCimetidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeCimetidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CephalexinThe metabolism of Cephalexin can be decreased when combined with Cimetidine.Approved, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cimetidine.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Cimetidine.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Cimetidine.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Cimetidine.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Cimetidine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Cimetidine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Cimetidine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Cimetidine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Cimetidine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Cimetidine.Approved
Cholic AcidCimetidine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CilnidipineThe serum concentration of Cilnidipine can be increased when it is combined with Cimetidine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Cimetidine.Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Cimetidine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cimetidine.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Cimetidine.Approved
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Cimetidine.Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Cimetidine.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Cimetidine.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Cimetidine.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Cimetidine.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Cimetidine resulting in a loss in efficacy.Approved, Nutraceutical
ClorindioneCimetidine may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Cimetidine.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Cimetidine.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cimetidine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cimetidine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Cimetidine.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Cimetidine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cimetidine.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Cimetidine.Approved
DalfampridineThe serum concentration of Dalfampridine can be increased when it is combined with Cimetidine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Cimetidine.Approved
DapoxetineThe metabolism of Dapoxetine can be decreased when combined with Cimetidine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Cimetidine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Cimetidine.Approved, Investigational
DarodipineThe serum concentration of Darodipine can be increased when it is combined with Cimetidine.Experimental
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Cimetidine.Approved
DasatinibCimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Cimetidine.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Cimetidine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Cimetidine.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Cimetidine.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Cimetidine.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Cimetidine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Cimetidine.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Cimetidine.Approved
DexmethylphenidateCimetidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Cimetidine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Cimetidine.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Cimetidine.Approved, Illicit, Vet Approved
DibenzepinThe metabolism of Dibenzepin can be decreased when combined with Cimetidine.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Cimetidine.Approved, Vet Approved
DicoumarolCimetidine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Cimetidine.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Cimetidine.Approved, Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Cimetidine.Approved
DiphenadioneCimetidine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Cimetidine.Approved
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Cimetidine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Cimetidine.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Cimetidine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Cimetidine.Approved
DosulepinThe metabolism of Dosulepin can be decreased when combined with Cimetidine.Approved
DotarizineThe serum concentration of Dotarizine can be increased when it is combined with Cimetidine.Investigational
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Cimetidine.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Cimetidine.Approved
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Cimetidine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cimetidine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Cimetidine.Approved, Investigational
DronabinolThe metabolism of Dronabinol can be decreased when combined with Cimetidine.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Cimetidine.Approved
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Cimetidine.Approved
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Cimetidine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cimetidine.Approved
EfonidipineThe serum concentration of Efonidipine can be increased when it is combined with Cimetidine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Cimetidine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cimetidine.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Cimetidine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Cimetidine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Cimetidine.Investigational
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Cimetidine.Approved, Investigational
EperisoneThe serum concentration of Eperisone can be increased when it is combined with Cimetidine.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Cimetidine.Approved, Investigational
EpirubicinThe serum concentration of Epirubicin can be increased when it is combined with Cimetidine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Cimetidine.Approved, Investigational
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Cimetidine.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Cimetidine.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Cimetidine.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
Ethyl biscoumacetateCimetidine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Cimetidine.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Cimetidine.Approved
EtoperidoneThe metabolism of Etoperidone can be decreased when combined with Cimetidine.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Cimetidine.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Cimetidine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cimetidine.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Cimetidine.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Cimetidine.Approved, Investigational
FendilineThe serum concentration of Fendiline can be increased when it is combined with Cimetidine.Withdrawn
Ferric CarboxymaltoseCimetidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateCimetidine can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateCimetidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimetidine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Cimetidine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Cimetidine.Approved, Withdrawn
FloxuridineThe serum concentration of the active metabolites of Floxuridine can be increased when Floxuridine is used in combination with Cimetidine.Approved
FluindioneCimetidine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Cimetidine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Cimetidine.Approved, Illicit
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Cimetidine.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Cimetidine.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Cimetidine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Cimetidine.Approved
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Cimetidine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Cimetidine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Cimetidine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Cimetidine is combined with Fosphenytoin.Approved
GabapentinThe serum concentration of Gabapentin can be increased when it is combined with Cimetidine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Cimetidine.Approved
GallopamilThe serum concentration of Gallopamil can be increased when it is combined with Cimetidine.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Cimetidine.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Cimetidine.Experimental
GlibornurideThe serum concentration of Glibornuride can be increased when it is combined with Cimetidine.Investigational, Withdrawn
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Cimetidine.Approved
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Cimetidine.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Cimetidine.Approved
GliquidoneThe serum concentration of Gliquidone can be increased when it is combined with Cimetidine.Approved, Investigational
GlisoxepideThe serum concentration of Glisoxepide can be increased when it is combined with Cimetidine.Approved, Investigational
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Cimetidine.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Cimetidine.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Cimetidine.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Cimetidine.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Cimetidine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Cimetidine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Cimetidine.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Cimetidine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cimetidine.Approved, Investigational
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Cimetidine.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Cimetidine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Cimetidine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Cimetidine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Cimetidine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Cimetidine.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Cimetidine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Cimetidine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Cimetidine.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Cimetidine.Approved
IndalpineThe metabolism of Indalpine can be decreased when combined with Cimetidine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Cimetidine.Approved
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Cimetidine.Approved, Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Cimetidine.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Cimetidine.Approved
IprindoleThe metabolism of Iprindole can be decreased when combined with Cimetidine.Experimental
IronCimetidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranCimetidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateCimetidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Cimetidine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Cimetidine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Cimetidine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Cimetidine.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Cimetidine.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Cimetidine.Approved
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Cimetidine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cimetidine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Cimetidine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Cimetidine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Cimetidine.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Cimetidine.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Cimetidine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Cimetidine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Cimetidine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Cimetidine.Approved, Vet Approved
LidoflazineThe serum concentration of Lidoflazine can be increased when it is combined with Cimetidine.Experimental
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Cimetidine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Cimetidine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Cimetidine.Approved, Investigational
LofepramineThe metabolism of Lofepramine can be decreased when combined with Cimetidine.Experimental
LomustineThe metabolism of Lomustine can be decreased when combined with Cimetidine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Cimetidine.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Cimetidine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Cimetidine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cimetidine.Approved, Investigational
LumacaftorThe serum concentration of Cimetidine can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Cimetidine.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Cimetidine.Approved
Magnesium SulfateThe serum concentration of Magnesium Sulfate can be increased when it is combined with Cimetidine.Approved, Vet Approved
ManidipineThe serum concentration of Manidipine can be increased when it is combined with Cimetidine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Cimetidine.Approved
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Cimetidine.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Cimetidine.Approved, Nutraceutical, Vet Approved
MephedroneMephedrone may decrease the sedative activities of Cimetidine.Investigational
MephentermineMephentermine may decrease the sedative activities of Cimetidine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Cimetidine.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Cimetidine.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Cimetidine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Cimetidine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Cimetidine.Approved, Investigational
MetahexamideThe serum concentration of Metahexamide can be increased when it is combined with Cimetidine.Experimental
MetforminThe serum concentration of Metformin can be increased when it is combined with Cimetidine.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Cimetidine.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Cimetidine.Approved, Illicit
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Cimetidine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Cimetidine.Experimental
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Cimetidine.Approved
MethylphenidateCimetidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Cimetidine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Cimetidine.Approved, Illicit, Withdrawn
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Cimetidine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cimetidine.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Cimetidine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Cimetidine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Cimetidine.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Cimetidine.Investigational, Withdrawn
MidomafetamineMidomafetamine may decrease the sedative activities of Cimetidine.Experimental, Illicit, Investigational
MilnacipranThe metabolism of Milnacipran can be decreased when combined with Cimetidine.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Cimetidine.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Cimetidine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Cimetidine.Approved
MMDAMMDA may decrease the sedative activities of Cimetidine.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cimetidine.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Cimetidine.Approved, Investigational
NaftopidilThe serum concentration of Naftopidil can be increased when it is combined with Cimetidine.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cimetidine.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Cimetidine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Cimetidine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Cimetidine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Cimetidine.Approved
NetupitantThe metabolism of Netupitant can be decreased when combined with Cimetidine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Cimetidine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Cimetidine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Cimetidine.Approved, Investigational
NicotineThe serum concentration of Nicotine can be increased when it is combined with Cimetidine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cimetidine.Approved
NiguldipineThe serum concentration of Niguldipine can be increased when it is combined with Cimetidine.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Cimetidine.Approved, Investigational
NiludipineThe serum concentration of Niludipine can be increased when it is combined with Cimetidine.Experimental
NilutamideThe metabolism of Nilutamide can be decreased when combined with Cimetidine.Approved
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Cimetidine.Approved, Investigational
NimesulideThe serum concentration of Nimesulide can be increased when it is combined with Cimetidine.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cimetidine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cimetidine.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Cimetidine.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Cimetidine.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Cimetidine.Approved, Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Cimetidine.Approved
OpipramolThe metabolism of Opipramol can be decreased when combined with Cimetidine.Investigational
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Cimetidine.Approved
OtiloniumThe serum concentration of Otilonium can be increased when it is combined with Cimetidine.Experimental, Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Cimetidine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Cimetidine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Cimetidine.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Cimetidine.Approved
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cimetidine.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Cimetidine.Approved
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Cimetidine.Approved, Vet Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Cimetidine.Approved, Investigational
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Cimetidine.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Cimetidine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Cimetidine.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Cimetidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Cimetidine.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Cimetidine.Approved, Investigational, Withdrawn
PhenindioneCimetidine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Cimetidine.Approved
PhenprocoumonCimetidine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative activities of Cimetidine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Cimetidine is combined with Phenytoin.Approved, Vet Approved
PinaveriumThe serum concentration of Pinaverium can be increased when it is combined with Cimetidine.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Cimetidine.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Cimetidine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Cimetidine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cimetidine.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Cimetidine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Cimetidine.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Cimetidine.Approved, Investigational, Vet Approved
PramipexoleThe serum concentration of Pramipexole can be increased when it is combined with Cimetidine.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Cimetidine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cimetidine.Approved
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Cimetidine.Approved, Vet Approved
PregabalinThe serum concentration of Pregabalin can be increased when it is combined with Cimetidine.Approved, Illicit, Investigational
PrenylamineThe serum concentration of Prenylamine can be increased when it is combined with Cimetidine.Withdrawn
PrimidoneThe metabolism of Primidone can be decreased when combined with Cimetidine.Approved, Vet Approved
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Cimetidine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Cimetidine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Cimetidine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Cimetidine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Cimetidine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Cimetidine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Cimetidine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Cimetidine.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Cimetidine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cimetidine.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Cimetidine.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Cimetidine.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Cimetidine.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cimetidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Cimetidine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Cimetidine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Cimetidine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Cimetidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cimetidine.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Cimetidine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Cimetidine.Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cimetidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Cimetidine.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Cimetidine.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Cimetidine.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Cimetidine.Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Cimetidine.Approved, Investigational
RoflumilastThe serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with Cimetidine.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Cimetidine.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Cimetidine.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Cimetidine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Cimetidine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Cimetidine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Cimetidine.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Cimetidine.Approved, Investigational
SelegilineThe metabolism of Selegiline can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Cimetidine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Cimetidine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Cimetidine.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Cimetidine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cimetidine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Cimetidine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Cimetidine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Cimetidine.Experimental
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cimetidine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Cimetidine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Cimetidine.Approved
TegafurThe serum concentration of the active metabolites of Tegafur can be increased when Tegafur is used in combination with Cimetidine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Cimetidine.Investigational, Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Cimetidine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Cimetidine.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Cimetidine.Withdrawn
TeriflunomideThe serum concentration of Cimetidine can be increased when it is combined with Teriflunomide.Approved
TerodilineThe serum concentration of Terodiline can be increased when it is combined with Cimetidine.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Cimetidine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Cimetidine.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Cimetidine.Approved
TetrahydropalmatineThe serum concentration of Tetrahydropalmatine can be increased when it is combined with Cimetidine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Cimetidine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Cimetidine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cimetidine.Approved, Withdrawn
TianeptineThe metabolism of Tianeptine can be decreased when combined with Cimetidine.Approved, Investigational
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Cimetidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Cimetidine.Approved
TioclomarolCimetidine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Cimetidine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Cimetidine.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Cimetidine.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Cimetidine.Approved, Investigational
TolazamideThe serum concentration of Tolazamide can be increased when it is combined with Cimetidine.Approved
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Cimetidine.Approved
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be increased when it is combined with Cimetidine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Cimetidine.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cimetidine.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Cimetidine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cimetidine.Approved, Investigational
TranilastThe serum concentration of Tranilast can be increased when it is combined with Cimetidine.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Cimetidine.Approved, Investigational
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Cimetidine.Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Cimetidine.Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Cimetidine.Approved, Investigational, Nutraceutical
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Cimetidine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Cimetidine.Approved, Investigational
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Cimetidine.Approved, Investigational
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Cimetidine.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Cimetidine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Cimetidine.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Cimetidine.Approved, Investigational
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Cimetidine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Cimetidine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Cimetidine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Cimetidine.Approved, Investigational
VinpocetineThe serum concentration of Vinpocetine can be increased when it is combined with Cimetidine.Investigational
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Cimetidine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Cimetidine.Approved
WarfarinCimetidine may increase the anticoagulant activities of Warfarin.Approved
XylometazolineThe serum concentration of Xylometazoline can be increased when it is combined with Cimetidine.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Cimetidine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Cimetidine.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Cimetidine.Approved, Illicit, Investigational
ZiconotideThe serum concentration of Ziconotide can be increased when it is combined with Cimetidine.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Cimetidine.Approved
ZimelidineThe metabolism of Zimelidine can be decreased when combined with Cimetidine.Withdrawn
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Cimetidine.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Cimetidine.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Cimetidine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Best effect when taken with food.
  • Limit caffeine intake.

References

Synthesis Reference

Saburo Uchikuga, Tomoyasu Tashiro, Yasuko Osawa, "Process for preparing the H.sub.2 -receptor antagonist cimetidine." U.S. Patent US4413129, issued March, 1972.

US4413129
General References
  1. Michnovicz JJ, Galbraith RA: Cimetidine inhibits catechol estrogen metabolism in women. Metabolism. 1991 Feb;40(2):170-4. [PubMed:1988774]
External Links
Human Metabolome Database
HMDB14644
KEGG Drug
D00295
KEGG Compound
C06952
PubChem Compound
2756
PubChem Substance
46505360
ChemSpider
2654
BindingDB
22889
ChEBI
3699
ChEMBL
CHEMBL30
Therapeutic Targets Database
DAP000338
PharmGKB
PA449001
IUPHAR
1231
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cimetidine
ATC Codes
A02BA01 — CimetidineA02BA51 — Cimetidine, combinations
AHFS Codes
  • 56:28.12 — Histamine H2-antagonists
FDA label
Download (420 KB)
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers2
1RecruitingOtherHealthy Volunteers1
1TerminatedNot AvailableGeneralized Anxiety Disorder (GAD)1
1Unknown StatusBasic ScienceHealthy Volunteers1
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentMelanoma (Skin) / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedPreventionPeptic ulcer haemorrhage1
3CompletedPreventionStress Ulcer Prophylaxis1
3CompletedPreventionUpper Gastrointestinal Hemorrhage1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastroesophageal Reflux Disease (GERD)1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Apotex inc
  • Contract pharmacal corp
  • Dava pharmaceuticals inc
  • Endo pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • L perrigo co
  • Perrigo co
  • Pliva inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Teva parenteral medicines inc
  • Actavis mid atlantic llc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Hi tech pharmacal co inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
Packagers
Dosage forms
FormRouteStrength
TabletOral200 mg
TabletOral300 mg
TabletOral600 mg
TabletOral400 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral800 mg/1
TabletOral200 mg/1
SolutionOral300 mg/5mL
TabletOral100 mg
SolutionIntramuscular; Intravenous150 mg
TabletOral400 mg
TabletOral800 mg
LiquidIntravenous6 mg
LiquidIntramuscular; Intravenous150 mg
LiquidOral300 mg
LiquidOral60 mg
Prices
Unit descriptionCostUnit
Cimetidine 800 mg tablet2.7USD tablet
Tagamet 400 mg tablet2.51USD tablet
Cimetidine 150 mg/ml vial1.67USD ml
Cimetidine powder1.48USD g
Cimetidine 400 mg tablet1.44USD tablet
Tagamet 300 mg tablet1.28USD tablet
Cimetidine 300 mg tablet0.93USD tablet
Cimetidine 200 mg tablet0.46USD tablet
Cimetidine HCl 300 mg/5ml Solution0.38USD ml
Tagamet hb 200 mg tablet0.37USD tablet
Apo-Cimetidine 800 mg Tablet0.27USD tablet
Mylan-Cimetidine 800 mg Tablet0.27USD tablet
Acid reducer 200 mg tablet0.21USD tablet
Apo-Cimetidine 600 mg Tablet0.18USD tablet
Mylan-Cimetidine 600 mg Tablet0.18USD tablet
Novo-Cimetine 600 mg Tablet0.18USD tablet
Nu-Cimet 600 mg Tablet0.18USD tablet
Apo-Cimetidine 400 mg Tablet0.14USD tablet
Mylan-Cimetidine 400 mg Tablet0.14USD tablet
Novo-Cimetine 400 mg Tablet0.14USD tablet
Nu-Cimet 400 mg Tablet0.14USD tablet
Apo-Cimetidine 200 mg Tablet0.09USD tablet
Apo-Cimetidine 300 mg Tablet0.09USD tablet
Mylan-Cimetidine 300 mg Tablet0.09USD tablet
Novo-Cimetine 300 mg Tablet0.09USD tablet
Nu-Cimet 300 mg Tablet0.09USD tablet
Heartburn relief 200 mg tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142 °CPhysProp
water solubility9380 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.40HANSCH,C ET AL. (1995)
logS-1.35ADME Research, USCD
Caco2 permeability-5.89ADME Research, USCD
pKa6.8TOMLINSON,E & HAFKENSCHEID,TL (1986)
Predicted Properties
PropertyValueSource
Water Solubility0.816 mg/mLALOGPS
logP0.44ALOGPS
logP-0.11ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)13.38ChemAxon
pKa (Strongest Basic)6.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area88.89 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity70.32 m3·mol-1ChemAxon
Polarizability27.47 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9855
Blood Brain Barrier-0.6782
Caco-2 permeable-0.6358
P-glycoprotein substrateSubstrate0.7887
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.7233
CYP450 2C9 substrateNon-substrate0.8048
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5795
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.5773
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9575
Ames testNon AMES toxic0.837
CarcinogenicityNon-carcinogens0.9579
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7341 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7983
hERG inhibition (predictor II)Non-inhibitor0.8745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-002b-9510000000-36ce01132725fd5bf5d8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4j-5900000000-122f9dbdf583bbe3dee8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-9300000000-39ee157d9e264867cfa4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-9000000000-6e876a668444c8277412
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-9000000000-85640be9b2799889fd02
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-9000000000-9b8d3eafde213bee6396
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4j-9000000000-b47e11697992a843f5e4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-9000000000-75ebe86c90f5ed341c57
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0aor-9000000000-d7302885bef7454b4db2
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-b2f3ab1b5ae1e2f8f8bb
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4i-0930000000-dbae8348b5c999cc664d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-052b-9600000000-8b4b94cd7303c9b9a0ef
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-9000000000-c23b62afdf4dff8c43db
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-9000000000-e477cd71a628f6adaf46
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-052e-9000000000-61584ad991262d50a01b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0zfr-1980000000-84e04b032e6f422e5b6b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aos-2900000000-e8d9297512335ce612fb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052b-9800000000-7235208cf21d7ea1f7ad
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9300000000-4996f6630fe29fccd7d1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9100000000-a5e040b5d19e189571ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9000000000-d8853f62b77fc7f6ab01
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9000000000-a5bdbde532dc871c2dc3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-114j-9000000000-89e11e4ab1dbea690ecd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-1000-9000000000-2968f2af0b540684c21f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0090000000-b6ea3493555e798b637d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0aos-2910000000-c696b6aba5edd10fe848
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00kb-9700000000-6b130a82094066468edc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-9200000000-6f64d37f41bf3bddd538
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-9100000000-f23125855effae49cbd8
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0aor-0900000000-9d38315a88e4b11bc9e7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0pb9-2940000000-eb44b45cbe2d97c7791c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-9511000000-75fc9243ad1eb9c79cb4
1H NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as imidazoles. These are compounds containing an imidazole ring, which is an aromatic five-member ring with two nitrogen atoms at positions 1 and 3, and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Imidazoles
Alternative Parents
Heteroaromatic compounds / Guanidines / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Dialkylthioethers / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Imines / Hydrocarbon derivatives
Substituents
Imidazole / Heteroaromatic compound / Guanidine / Thioether / Carboximidamide / Sulfenyl compound / Propargyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound / Dialkylthioether / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, guanidines, aliphatic sulfide, nitrile (CHEBI:3699)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Hernandez-Munoz R, Montiel-Ruiz C, Vazquez-Martinez O: Gastric mucosal cell proliferation in ethanol-induced chronic mucosal injury is related to oxidative stress and lipid peroxidation in rats. Lab Invest. 2000 Aug;80(8):1161-9. [PubMed:10950107]
  3. Kuint J, Linder N, Reichman B: Hypoxemia associated with cimetidine therapy in a newborn infant. Am J Perinatol. 1996 Jul;13(5):301-3. [PubMed:8863950]
  4. Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. Epub 2006 May 24. [PubMed:16723495]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
4. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Trimethylamine monooxygenase activity
Specific Function
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an impor...
Gene Name
FMO3
Uniprot ID
P31513
Uniprot Name
Dimethylaniline monooxygenase [N-oxide-forming] 3
Molecular Weight
60032.975 Da
References
  1. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 2000 Sep;1(2):181-91. [PubMed:11465082]
  2. Cashman JR, Park SB, Berkman CE, Cashman LE: Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans. Chem Biol Interact. 1995 Apr 28;96(1):33-46. [PubMed:7720103]
  3. Hai X, Adams E, Hoogmartens J, Van Schepdael A: Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms. Electrophoresis. 2009 Apr;30(7):1248-57. doi: 10.1002/elps.200800604. [PubMed:19283698]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Nadp binding
Specific Function
This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.
Gene Name
FMO1
Uniprot ID
Q01740
Uniprot Name
Dimethylaniline monooxygenase [N-oxide-forming] 1
Molecular Weight
60310.285 Da
References
  1. Hai X, Adams E, Hoogmartens J, Van Schepdael A: Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms. Electrophoresis. 2009 Apr;30(7):1248-57. doi: 10.1002/elps.200800604. [PubMed:19283698]
  2. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 2000 Sep;1(2):181-91. [PubMed:11465082]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  2. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  4. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. [PubMed:11042226]
  5. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365]
  2. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
  3. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Biophys Res Commun. 2002 Aug 23;296(3):644-50. [PubMed:12176030]
  4. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712]
  5. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798]
  6. Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA: A transfected cell model for the renal toxin transporter, rOCT2. Toxicol Sci. 1999 Feb;47(2):181-6. [PubMed:10220855]
  7. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071]
  8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  9. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
  3. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Biophys Res Commun. 2002 Aug 23;296(3):644-50. [PubMed:12176030]
  4. Zhang L, Dresser MJ, Chun JK, Babbitt PC, Giacomini KM: Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem. 1997 Jun 27;272(26):16548-54. [PubMed:9195965]
  5. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712]
  6. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798]
  7. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH: Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol. 2001 Aug;21(16):5471-7. [PubMed:11463829]
  8. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678]
  9. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Grundemann D, Schechinger B, Rappold GA, Schomig E: Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998 Sep;1(5):349-51. [PubMed:10196521]
  2. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924]
  3. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem. 1998 Jun 26;273(26):15971-9. [PubMed:9632645]
  4. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Wu X, Prasad PD, Leibach FH, Ganapathy V: cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998 May 29;246(3):589-95. [PubMed:9618255]
  2. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
  3. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  3. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115]
  4. Burckhardt BC, Brai S, Wallis S, Krick W, Wolff NA, Burckhardt G: Transport of cimetidine by flounder and human renal organic anion transporter 1. Am J Physiol Renal Physiol. 2003 Mar;284(3):F503-9. Epub 2002 Nov 12. [PubMed:12429554]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  3. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
  4. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
  5. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
  6. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115]
  7. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720]
  8. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  9. Bakhiya A, Bahn A, Burckhardt G, Wolff N: Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem. 2003;13(5):249-56. [PubMed:14586168]
  10. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]
  11. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
References
  1. Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, Kumar V, Stevens JC: Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44. doi: 10.1124/jpet.110.170753. Epub 2010 Jun 2. [PubMed:20519552]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18